Here's a look at some of the latest news regarding ophthalmic drugs and therapies from the past week.
- International ophthalmic company Nicox S.A. announced on Tuesday that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for AC-170 — a novel, proprietary, cetirizine eye drop formulation, for the treatment of ocular itching associated with allergic conjunctivitis. Additionally, the FDA had granted Priority Review and had assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 18, 2016.
- Earlier this week, Ophthotech Corporation announced it had completed patient recruitment for its Phase 3 trial of Fovista® (pegpleranib), anti-PDGF therapy, in combination with Eylea® (aflibercept) or Avastin® (bevacizumab) for the treatment of wet age-related macular degeneration (AMD).
- Biopharmaceutical company NEMUS Bioscience, Inc. reported data obtains from its research and commercialization partner, the University of Mississippi (UM), regarding the effects of NB1111 — the proprietary NEMUS prodrug of tetrahydrocannabinol (THC). The data showed in a rabbit normal ocular pressure model NB1111 provided superior tissue penetration and concentration, whether administered in a solid lipid nanoparticle (SLN) or in an eye drop emulsion, when compared to standard THC in the same eye drop vehicles.
- Perrigo Company plc has reached a definitive agreement to sell its U.S. Vitamins, Minerals & Supplements (VMS) business to International Vitamin Corporation (IVC). The transaction is subject to customary closing conditions and is expected to close by early August.